Evidence map›Paper›PMID 23844703›Full record

ArticleImmunology2013

The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Zhaohua Lu, Michael J Rynkiewicz, Chiou-Ying Yang, Guillermo Madico, Hillary M Perkins, Qi Wang, Catherine E Costello, Joseph Zaia, Barbara A Seaton, Jacqueline Sharon

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. The Tip ofMicroorganisms · 2022
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhaohua LuDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA.
Michael J Rynkiewicz
Chiou-Ying Yang
Guillermo Madico
Hillary M Perkins
Qi Wang
Catherine E Costello
Joseph Zaia
Barbara A Seaton
Jacqueline Sharon
Boston University · US

Funding

Mass Spectrometry Resource for Biology and MedicineP41GM104603 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 2012 to 2017
$10.4M
NIAID NIH HHS HHSN272200900054CNIGMS NIH HHS P41 GM104603
6 · The paper itself

Abstract

We have previously described two types of protective B-cell epitopes in the O-antigen (OAg) of the Gram-negative bacterium Francisella tularensis: repeating internal epitopes targeted by the vast majority of anti-OAg monoclonal antibodies (mAbs), and a non-overlapping epitope at the non-reducing end targeted by the previously unique IgG2a mAb FB11. We have now generated and characterized three mAbs specific for the non-reducing end of F. tularensis OAg, partially encoded by the same variable region germline genes, indicating that they target the same epitope. Like FB11, the new mAbs, Ab63 (IgG3), N213 (IgG3) and N62 (IgG2b), had higher antigen-binding bivalent avidity than internally binding anti-OAg mAbs, and an oligosaccharide containing a single OAg repeat was sufficient for optimal inhibition of their antigen-binding. The X-ray crystal structure of N62 Fab showed that the antigen-binding site is lined mainly by aromatic amino acids that form a small cavity, which can accommodate no more than one and a third sugar residues, indicating that N62 binds mainly to the terminal Qui4NFm residue at the nonreducing end of OAg. In efficacy studies with mice infected intranasally with the highly virulent F. tularensis strain SchuS4, N62, N213 and Ab63 prolonged survival and reduced blood bacterial burden. These results yield insights into how antibodies to non-reducing ends of microbial polysaccharides can contribute to immune protection despite the smaller size of their target epitopes compared with antibodies to internal polysaccharide regions.

Indexed as

AnimalsAntibodies, BispecificAntibodies, MonoclonalAntibody AffinityBacterial LoadBinding Sites, AntibodyCells, CulturedCrystallizationEpitopes, B-LymphocyteFemaleFrancisella tularensisHumansImmunity, HumoralMiceMice, Inbred BALB CO AntigensAntibodies, BispecificAntibodies, MonoclonalEpitopes, B-LymphocyteO Antigensbacteria/bacterial immunityendotoxin/lipopolysaccharideepitopesimmunoglobulinsvaccines

Identifiers

PMID23844703
PMCPMC3800442
OpenAlexW2058872521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.